

List of abbreviations	5
Introduction	7
Definitions, development and economics	11
Biosimilars vs reference biologics: variability and comparability	23
How are biosimilars approved in Europe and the USA?	35
Biosimilars in Europe: from regulatory approval to clinical practice	61
Intended copy biologics: what are they and does it matter?	75
Impact of intended copy biologics on medicines use	93
Solutions to the regulatory problem and the WHO approach	101
Practical steps when quality is uncertain	107
Biosimilars globally in endocrinology, renal medicine, hematology, oncology, and immunology	115
Conclusions	151
Index	157